B-cell & Hematologic Antigens

Cat. No.

AT0805

CAS No.

1169717-01-4

PF-5212374 (TRU-015)

Synonyms: TRU-015

PF-5212374 (TRU-015) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD20 (MS4A1). This antibody features a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with a molecular weight of approximately 145 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Cat. No.

AT0824

CAS No.

156586-90-2

Cedelizumab

Synonyms: RWJ 49004

Cedelizumab (RWJ 49004) is an IgG4 monoclonal antibody designed to specifically target CD4, a glycoprotein expressed on the surface of immune cells such as T helper cells. This antibody exhibits immunosuppressive properties, making it a valuable tool for research into immune response modulation and potential therapeutic applications in autoimmune diseases and transplant rejection.

Cat. No.

AT0844

CAS No.

174722-31-7

Rituximab

Synonyms: Anti-Human CD20 type I; Chimeric Antibody

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Cat. No.

AT0848

CAS No.

1622075-65-3

Moxetumomab

Moxetumomab is a human IgG1 κ monoclonal antibody targeting CD22. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0858

CAS No.

2607644-43-7

Zeripatamig

Synonyms: TG-1801

Zeripatamig is a human IgG1 κ monoclonal antibody targeting both CD19 and CD47 antigens. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Cat. No.

AT0882

CAS No.

1929549-92-7

Ianalumab

Synonyms: VAY-736

Ianalumab (VAY-736) is a humanized, decarboxylated monoclonal antibody that specifically targets BAFF-R (B-cell activating factor receptor). This antibody effectively blocks the interaction between BAFF (B-cell activating factor) and its receptor BAFF-R, thereby inhibiting the BAFF-mediated protection from apoptosis. Additionally, Ianalumab promotes antibody-dependent cellular cytotoxicity (ADCC) through the activation of effector cells mediated by the immune receptor tyrosine-based activation motif (ITAM). This dual mechanism of action makes Ianalumab a valuable tool for research into B-cell regulation and autoimmune disease therapies.

Cat. No.

AT0919

CAS No.

2234335-84-1

Pivekimab

Pivekimab is a human IgG1 monoclonal antibody engineered to specifically target interleukin-3 (IL-3) and CD123. This antibody serves as the foundational component in the synthesis of Pivekimab Sunirine, a targeted CD123-directed antibody-drug conjugate (ADC) utilized in therapeutic applications. Pivekimab is primarily employed in research focused on blastic plasmacytoid dendritic cell neoplasm (BPDCN), providing a critical tool for advancing studies in this area of oncology.

Cat. No.

AT0927

CAS No.

1269764-99-9

Coltuximab

Coltuximab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD19. This biologic is constructed from human immunoglobulin G1 (huIgG1) heavy chains and human kappa (huκ) light chains, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT0928

CAS No.

1864871-20-4

Cusatuzumab

Synonyms: ARGX-110

Cusatuzumab (ARGX-110) is a humanized monoclonal antibody targeting CD70. It exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) and effectively blocks the CD70/CD27 signaling pathway. By inhibiting this pathway, cusatuzumab reduces the population of leukemia stem cells (LSCs) and induces gene signatures associated with myeloid differentiation and apoptosis. This antibody is particularly useful in research focused on the pathophysiology and potential therapeutic interventions for leukemia.

Cat. No.

AT0930

CAS No.

166089-32-3

Lintuzumab

Synonyms: HuM-195

Lintuzumab (HUM-195) is a humanized monoclonal antibody targeting CD33, designed to modulate immune responses in acute myeloid leukemia (AML). By reducing the production of TNFα-induced pro-inflammatory cytokines and chemokines, Lintuzumab effectively suppresses inflammatory pathways in AML cells. It facilitates tumor cell eradication via mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), demonstrating efficacy against both multidrug-resistant (MDR) and non-resistant AML cell lines, as well as primary samples from AML patients. In vivo studies have shown that Lintuzumab significantly enhances survival rates and diminishes tumor burden in murine models, highlighting its potential as a therapeutic agent in oncology research.

Cat. No.

AT0932

Anti-IL-3Ra/CD123 Antibody (SNG-CD123A)

Synonyms: SNG-CD123A

Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-3 receptor alpha, also known as CD123. This antibody has a molecular weight of approximately 146.14 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This antibody is designed for precise targeting, making it suitable for a range of research applications focusing on the biology and pathophysiology of IL-3Ra/CD123.

Cat. No.

AT0933

LGN-523 (AML-01)

Synonyms: AML-01

LGN-523 (AML-01) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD98. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, featuring a predicted molecular weight of 145.66 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. LGN-523 (AML-01) is suitable for a variety of research applications focusing on the role of CD98 in cellular processes.

Cat. No.

AT0934

DFRF4539A (RG-7598)

Synonyms: RG-7598

DFRF4539A (RG-7598) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets FcRH5/IRTA2/CD307e, a protein expressed on the surface of certain immune cells. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a molecular weight of approximately 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Cat. No.

AT0940

CAS No.

2088770-90-3

Brentuximab

Brentuximab is a monoclonal antibody that specifically targets CD30, a cell surface antigen. This antibody is conjugated with monomethyl auristatin E (MMAE), resulting in the antibody-drug conjugate known as Brentuximab vedotin. This conjugate has been shown to induce apoptosis in primary effusion lymphoma cells and demonstrates potent antitumor activity. In vitro studies reveal that Brentuximab vedotin has an IC50 of 10 nM against human CD30-positive cancer cells, highlighting its efficacy in targeting and eliminating malignant cells expressing CD30.

Cat. No.

AT0946

CAS No.

680188-33-4

Ibalizumab

Synonyms: TMB-355; TNX-355

Ibalizumab (TMB-355) is a humanized IgG4 monoclonal antibody designed to inhibit HIV-1 entry into cells by specifically binding to the CD4 receptor. This targeted mechanism makes Ibalizumab a valuable tool for research into the prevention and treatment of HIV-1 infection.

Cat. No.

AT0949

CAS No.

1826020-80-7

Gatralimab

Synonyms: GZ-402668

Gatralimab (GZ-402668) is an IgG1 monoclonal antibody specifically designed to target CD52. This antibody is utilized in various research studies to investigate its potential therapeutic applications and mechanism of action in modulating immune responses.

Cat. No.

AT0959

Anti-CD4 Antibody (TRX1)

Synonyms: TRX1

The Anti-CD4 Antibody (TRX1) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CD4 receptor, a critical molecule involved in the immune response. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT0965

CAS No.

205923-57-5

Epratuzumab

Synonyms: Antibody hLL 2

Epratuzumab, designated as hLL 2, is a humanized IgG1 monoclonal antibody targeting CD22, a cell surface antigen expressed predominantly on B cells. This antibody functions not only as an immunomodulatory agent but also as a tumor-imaging agent due to its specific binding to CD22. Epratuzumab has demonstrated the ability to induce phosphorylation of CD22, which plays a critical role in the modulation of B cell signaling and function. The primary applications of Epratuzumab have been in the study of non-Hodgkin’s lymphomas (NHL) and various autoimmune diseases, where it has shown potential in modulating immune responses and providing diagnostic imaging insights.

Cat. No.

AT0970

CAS No.

1690318-25-2

Crizanlizumab

Crizanlizumab is a monoclonal antibody that targets P-selectin, effectively inhibiting its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). By blocking this interaction, Crizanlizumab plays a crucial role in preventing vaso-occlusive crises (VOCs), making it a valuable tool for the study and research of sickle cell disease pathophysiology and therapeutic interventions.

Cat. No.

AT0986

Anti-CD5 Antibody

Cat. No.

AT1000

CAS No.

2871775-98-1

Bexatamig

Bexatamig is a bispecific antibody engineered to target IL3RA and NCR1. Its structure comprises a heavy gamma 1 chain variable region and constant region 1 linked to a light kappa chain, further conjugated to the kappa constant region and heavy constant regions 2 and 3. This configuration enables dual specificity, providing a valuable tool for research into the biological pathways and potential therapeutic applications involving these targets.

Cat. No.

AT1019

CAS No.

728917-18-8

Veltuzumab

Synonyms: IMMU-106; hA20

Veltuzumab (IMMU-106) is a humanized monoclonal antibody targeting CD20, demonstrating a potent efficacy with an EC50 value ranging between 0.08-0.09 μg/mL in the Daudi cell line. This antibody is primarily utilized in oncological research, particularly focusing on non-Hodgkin lymphoma (NHL) and other related cancer studies.

Cat. No.

AT1057

CAS No.

2763746-69-4

Bezetabart

Bezetabart is a human IgG1 κ monoclonal antibody targeting CD74. For accurate experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT1100

CAS No.

182912-58-9

Clenoliximab

Synonyms: IDEC-151

Clenoliximab (IDEC-151) is a chimeric monoclonal antibody derived from macaque and human sources, classified within the immunoglobulin G4 subclass. It exhibits specificity for the CD4 molecule expressed on the surface of T lymphocytes. This antibody is primarily utilized in research focused on elucidating the pathophysiology and potential therapeutic interventions for rheumatoid arthritis.

Cat. No.

AT1104

CAS No.

1422527-84-1

Tafasitamab

Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix

Tafasitamab (XmAb5574) is an Fc-engineered, humanized monoclonal antibody specifically designed to target the CD19 antigen on human B-cell surfaces. This antibody's modifications enhance its binding affinity and efficacy in engaging immune effector functions, making it a critical tool in research focused on B-cell related diseases and therapeutics.